A New Way to Deliver Isatuximab in Myeloma: Safety Insights on the On-Body Injector (OBI) | #EHA2026

Isatuximab has become an important treatment option for patients with multiple myeloma, but traditional intravenous administration can require lengthy clinic visits. At EHA 2026, researchers presented new safety data on the Isatuximab On-Body Injector (OBI), an innovative delivery system designed to simplify treatment administration and improve the patient experience.

In this video, we review the latest findings on the safety, tolerability, and feasibility of the Isatuximab OBI, including rates of administration-related reactions, device performance, and what this new approach could mean for patients and healthcare providers.

 If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/628617/src=htu

For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity
Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer!

Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_source=social+media&utm_medium=htu+youtube&utm_campaign=htu-curehub&utm_content=general
Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.